News Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 05/04/21 Summary ToggleClearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021 PDF Version 05/03/21 Summary ToggleClearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis PDF Version 04/05/21 Summary ToggleClearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit PDF Version 03/10/21 Summary ToggleClearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update PDF Version 03/02/21 Summary ToggleClearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD PDF Version 02/24/21 Summary ToggleClearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021 PDF Version 02/23/21 Summary ToggleClearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021 PDF Version 02/16/21 Summary ToggleClearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program PDF Version 02/08/21 Summary ToggleClearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting PDF Version 01/12/21 Summary ToggleClearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Next page Last page Last
